Ivabradine
As of the edition of 20 October 2026, Ivabradine is a small molecule: marketed, first approved in 2005 (EU); acts on HCN4; US protection ends in 2026.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2019
- Kind
- Small molecule
- Brand name
- Corlanor
- First approved
- 25 October 2005 (EU)
- Approvals on record
- 10 in 4 regions
- Holder of the most recent approval
- Ono Pharmaceutical; 5 holders in all
- Withdrawn from market
- 6 December 2018 (in some regions)
- Registered trials
- 59, 8 stopped early
- Disease areas
- Heart and blood vessels; Infections; Lungs and airways; Nervous system; Blood and lymph; Cancer
US protection
US protection ends in 2026.
The last listed US drug-substance patent ends in 2026. The application that gives this date is held by Amgen.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product14 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 14 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
3 companies on route B because of this drug.
Companies on route B for this drug
In the product3 companies are on route B because of Ivabradine.
See the 3 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HCN4 | Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 | Q9Y3Q4 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 10 | 5 | 1 | 0 |
| Phase 1 | 2 | 1 | 1 | 0 |
| Phase 2 | 10 | 4 | 0 | 1 |
| Phase 3 | 17 | 11 | 2 | 2 |
| Phase 4 | 20 | 6 | 2 | 5 |
| All trials | 59 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Servier | Applicant | 2005 to now |
| Amgen | Applicant and Lead sponsor of trials | 2015 to now |
| "Anpharm" Przedsiębiorstwo Farmaceutyczne | Later holder | 2015 to now |
| Ono Pharmaceutical | Applicant | 2019 to now |